Cargando…
Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity
Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues to be immunogenicity exemplified by the anti-...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466112/ https://www.ncbi.nlm.nih.gov/pubmed/30577664 http://dx.doi.org/10.3390/biomedicines7010001 |